This site is intended for U.S. health care professionals.
This site is intended for U.S. health care professionals.

Biosimilars PDF Resource Summary

Pathways to Biosimilars: Development and Implementation

A Self-Directed Learning Experience

Welcome to “Pathways to Biosimilars: Development and Implementation”

Through this self-directed learning experience, you will:

Recognize that biosimilars were introduced to lower costs to the health care system1,2

Understand the rigorous development and FDA approval processes for biosimilars3

Gain ideas for adopting biosimilars in your health care system or practice

Ready to begin?

Continue to Why Biosimilars Matter

FDA, US Food and Drug Administration

References: 1. Biosimilars Action Plan. Balancing Innovation and Competition. US Food and Drug Administration. July 2018. Accessed March 22, 2023. 2. Mulcahy AW, Hlávka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Quarterly. 2018 Mar;7(4). Accessed March 22, 2023. 3. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. US Food and Drug Administration. April 2015. Updated April 24, 2020. Accessed March 22, 2023.